- Home
- VERX vs AUPH Comparison
VERX vs AUPH Comparison
Compare VERX & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VERX | AUPH |
|---|---|---|
| Founded | 1978 | 1993 |
| Country | United States | Canada |
| Employees | 2100 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | VERX | AUPH |
|---|---|---|
| Price | $13.38 | $15.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $24.25 | $17.25 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $748,444,000.00 | $283,055,000.00 |
| Revenue This Year | $12.78 | $17.54 |
| Revenue Next Year | $11.61 | $15.74 |
| P/E Ratio | $302.25 | ★ $61.82 |
| Revenue Growth | 12.25 | ★ 20.38 |
| 52 Week Low | $10.59 | $7.29 |
| 52 Week High | $42.44 | $16.88 |
Technical Indicators
Market Signals| Indicator | VERX | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 52.70 | 45.54 |
| Support Level | $11.38 | $14.53 |
| Resistance Level | $13.73 | $16.38 |
| Average True Range (ATR) | 0.79 | 0.62 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 38.07 | 45.84 |
Price Performance
Historical ComparisonAbout VERX Vertex Inc.
Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. It provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting, among others. The company derives revenue from software subscriptions.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.